What&#x27;s Next for Advanced Melanoma?

Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

NCCN Guideline Updates on ctDNA Stance in MCC and Colon, Rectal Cancer

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Illustration of a clipboard with the word "Guidelines" on top of the page, followed by a check list

Kyle Doherty

Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.

Cosibelimab Approved by FDA for Metastatic, Locally Advanced Cutaneous Squamous Cell Carcinoma

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Kristi Rosa

Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma

An FDA approval was granted for cosibelimab-ipdl for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

Ashling Wahner

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated melanoma.

Related Content

Michelle Kirschner, RN, MSN, ACNP, APRN-BC

Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

NCCN Guideline Updates on ctDNA Stance in MCC and Colon, Rectal Cancer

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Kyle Doherty

Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.

Cosibelimab Approved by FDA for Metastatic, Locally Advanced Cutaneous Squamous Cell Carcinoma

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Kristi Rosa

Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma

An FDA approval was granted for cosibelimab-ipdl for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

Ashling Wahner